Comparative efficacy of AAC and ibuprofen versus lasmiditan, ubrogepant, and rimegepant for the acute treatment of episodic migraine in adults: a systematic review and network meta-analysis
Ashoke Mitra, Billy Franks, Richard Petruschke, Abhijeet Dhiman, Nitu Bansal · 2026
Read Comparative efficacy of AAC and ibuprofen versus lasmiditan, ubrogepant, and rimegepant for the acute treatment of episodic migraine in adults: a systematic review and network meta-analysis by Ashoke Mitra, Billy Franks, Richard Petruschke, Abhijeet Dhiman, Nitu Bansal (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13619513.txt.
Description
Ashoke Mitra and co-authors compare migraine treatments in a 2026 systematic review and network analysis of trials. Many drug options exist for acute migraine, but common over-the-counter choices are rarely tested directly against newer prescription drugs. The therapy under study pairs an antihistamine and caffeine combination with ibuprofen.
Because head-to-head trials are scarce, the team combined randomized trials into a network that allows indirect comparison across treatments. Rivals included lasmiditan and the newer CGRP-blocking drugs ubrogepant and rimegepant. The results help adults with episodic migraine and their doctors judge whether a cheap shelf option can match newer prescription drugs.
Catalog record
| CREATOR | Ashoke Mitra, Billy Franks, Richard Petruschke, Abhijeet Dhiman, Nitu Bansal |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |